By James A. Levine
by James A. Levine, MD, PhD, Professor
Entrepreneurs have the DACMAR Advantage
6-steps for successful biotech start-ups
Age: All ages
Pagination: 152 pages
Size: 230 x 163 mm
Language: English
Publication: August 2024
ISBN: 978-2-38427-221-1 (print)/ 978-2-38427-222-8 (ePub)
Free
DACMAR is a FAST BUSINESS GUIDE for newbie biotech entrepreneurs. GIVE ME 5 MINUTES: If you know nothing about modern biotech business lingo, grab this book and read the LEARNING BOXES. In 5 minutes, you’ll know DACMAR – you’ll know enough! If you WANT TO BUILD a SUCCESSFUL biotech start-up that delivers new medicines, read the DACMAR ADVANTAGE. Each chapter will take you 5 minutes. By the time you are finished in less than 2 hours, you’ll have the DACMAR ADVANTGE. DACMAR is the basic business building blocks for a biotech start-up. At the conclusion of the DACMAR ADVANTAGE, I take you to the WIN! Your start-up flourishes: you are acquired or go public. Through your entrepreneurial genius, millions of patients will be saved. The DACMAR ADVANTAGE will help you win.
Dr. Levine, President Fondation Ipsen, has three decades of experience in the healthcare sector principally at Mayo Clinic. For the last 6 years he has been President of Fondation Ipsen, an international science foundation focused on biotech innovation in Rare Diseases. A physician and scientist, James has published more than 200 articles, six papers in Science and Nature plus articles in journals such as, the New England Journal of Medicine, Lancet and JAMA. He has written four books published in 19 languages in 37 countries. His business training, focused on entrepreneurship, was from Harvard Business School. With a background in wearable technologies, data gathering and data analytics, and with more than 100 patents and trademarks, Levine helped found 35 companies. He was the Innovator of the Year in the state of Minnesota, the World Trade Fair and NASA. Under the Mayo Clinic NEAT Trademarks, Levine’s team delivered scalable health solutions to 72 US corporations. A great deal of James’ work focusses on biotech development, scalable health solutions and business opportunities in underserved regions in the United States, France and low/middle countries such as the Democratic Republic of Congo, Cote d’Ivoire, Afghanistan, Jamaica, Asia, Kenya and India. Consulting to the President of the United States, the US State Department, US Army and internationally, James in 2018 was awarded the President’s Medal for promoting social embeddedness. 300 million people live with rare diseases without effective cures. Sustainable solutions require the efficient use of capital to optimize biotechnology companies, maximize impact and minimize suffering.